Lexicon Pharmaceuticals (LXRX) Cash from Financing Activities (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Cash from Financing Activities of $88.8 million for Q1 2026, up 15616.78% year-over-year from N/an in Q1 2025, and up 3132.32% quarter-over-quarter from -$2.9 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Cash from Financing Activities for 17 consecutive years, with $88.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 15616.78% year-over-year to $88.8 million; the TTM figure through Mar 2026 stood at $40.8 million (up 2642.28% YoY), while the FY2025 annual figure was -$48.5 million, down 120.35% from the prior year.
- Cash from Financing Activities improved to $88.8 million in Q1 2026 per LXRX's latest filing, from -$2.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $239.4 million in Q1 2024 and bottomed at -$45.0 million in Q2 2025.
- Historically, Cash from Financing Activities has averaged $40.6 million across 5 years, with a median of -$14000.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 29151.33% — and 2025, when it tumbled 321328.57%.
- Lexicon Pharmaceuticals' Cash from Financing Activities stood at $24.9 million in 2022, then sank by 100.0% to -$1000.0 in 2023, then sank by 10300.0% to -$104000.0 in 2024, then tumbled by 2714.42% to -$2.9 million in 2025, then jumped by 3132.32% to $88.8 million in 2026.
- Business Quant data shows LXRX's Cash from Financing Activities at $88.8 million in Q1 2026, -$2.9 million in Q4 2025, and -$45.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | -512,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -512,000.00 |
| Jun 30, 2026 | -512,000.00 |
| Mar 31, 2026 | 88.76 Mn |
| Mar 31, 2026 | 88.76 Mn |
| Dec 31, 2025 | -2.93 Mn |
| Dec 31, 2025 | -2.93 Mn |
| Jun 30, 2025 | -45.00 Mn |
| Jun 30, 2025 | -45.00 Mn |
| Mar 31, 2025 | -572,000.00 |
| Mar 31, 2025 | -572,000.00 |
| Dec 31, 2024 | -104,000.00 |
| Dec 31, 2024 | -104,000.00 |
| Sep 30, 2024 | -916,000.00 |
| Sep 30, 2024 | -916,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Mar 31, 2024 | 239.38 Mn |
| Mar 31, 2024 | 239.38 Mn |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |